NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSPOWDER
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
GLUCAGON (glucagon) by Fresenius Kabi is stomach, small bowel, and colon. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glucagon is a peptide hormone powder formulation administered via intramuscular, intravenous, or subcutaneous injection, used primarily for emergency treatment of severe hypoglycemia in diabetic patients. It works by stimulating the release of glucose from hepatic glycogen stores in the stomach, small bowel, and colon. The product is indicated for rapid reversal of hypoglycemic episodes when oral glucose cannot be administered.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30); teams likely focused on market maintenance and efficiency rather than aggressive expansion.
Mechanism of Action
stomach, small bowel, and colon.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Started May 2026
300 enrolled
Obesity or Overweight
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
Started Apr 2026
50 enrolled
Laxity; Skin
Glucagon Resistance in Patients With MASLD and T2DM
Started Jan 2026
24 enrolled
Metabolic Associated Fatty Liver DiseaseType 2 Diabetes (T2DM)
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
Started Nov 2025
24 enrolled
Wrinkle
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Started Oct 2025
10 enrolled
glp1 AgonistGene ExpressionSkin Laxity
Worked on GLUCAGON at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.